Abiraterone in Prostate Cancer

Clinical Cancer Research, 04/06/2012Stein MN et al.

Abiraterone's efficacy shows the importance of androgen signaling in patients with castrate–resistant metastatic disease, with additional confirmation from recent studies of other novel agents such as MDV3100, an androgen receptor signaling inhibitor.